

Technical recommendations for analyzing oxylipins by liquid chromatography–mass spectrometry

Nils Helge Schebb^{*,#1}, Nadja Kampschulte¹, Gerhard Hagn², Kathrin Plitzko¹, Sven W. Meckelmann³, Soumita Ghosh⁴, Robin Joshi⁴, Julia Kuligowski⁵, Dajana Vuckovic⁶, Marina T. Botana^{2,7}, Ángel Sánchez-Illana⁸, Fereshteh Zandkarimi⁹, Aditi Das¹⁰, Jun Yang¹¹, Louis Schmidt¹², Antonio Checa², Helen M. Roche^{13,14}, Aaron M. Armando¹⁵, Matthew L. Edin¹⁶, Fred B. Lih¹⁶, Juan J. Aristizabal-Henao¹⁷, Sayuri Miyamoto¹⁸, Francesca Giuffrida¹⁹, Arie H. Moussaieff²⁰, Rosário Domingues²¹, Michael Rothe²², Christine Hinz²³, Ujjalkumar Subhash Das⁴, Katharina M. Rund¹, Ameer Y. Taha²⁴, Robert K. Hofstetter²⁵, Markus Werner²⁵, Oliver Werz²⁵, Astrid S. Kahnt²⁶, Justine Bertrand-Michel²⁷, Pauline Le Faouder²⁷, Robert Gurke^{28,29,30}, Dominique Thomas^{28,29,30}, Federico Torta^{31,32}, Ivana Milic³³, Irundika H. K. Dias³⁴, Corinne M. Spickett³³, Denise Biagini³⁵, Tommaso Lomonaco³⁵, Helena Idborg³⁶, Jun-Yan Liu³⁷, Maria Fedorova³⁸, David A. Ford³⁹, Anne Barden⁴⁰, Trevor A Mori⁴⁰, Paul D. Kennedy⁴¹, Kirk Maxey⁴¹, Julijana Ivanisevic⁴², Hector Gallart-Ayala⁴², Cécile Gladine⁴³, Markus Wenk^{44,45}, Jean-Marie Galano⁴⁶, Thierry Durand⁴⁶, Ken D. Stark⁴⁷, Coral Barbas⁴⁸, Ulrike Garscha¹², Stacy L. Gelhaus^{49,50}, Uta Ceglarek⁵¹, Nicolas Flamand⁵², Julian L. Griffin⁵³, Robert Ahrends⁵⁴, Makoto Arita⁵⁵, Darryl C. Zeldin¹⁶, Francisco J. Schopfer⁵⁰, Oswald Quehenberger¹⁵, Randall Julian⁵⁶, Anna Nicolaou⁵⁷, Ian A. Blair⁵⁸, Michael P. Murphy⁵⁹, Bruce D. Hammock¹¹, Bruce Freeman⁵⁰, Gerhard Liebisch⁶⁰, Charles N. Serhan⁶¹, Harald C. Köfeler⁶², Per-Johan Jakobsson³⁶, Dieter Steinhilber²⁶, Michael H. Gelb⁶³, Michal Holčapek⁶⁴, Ruth Andrew⁶⁵, Martin Giera⁶⁶, Garret A. FitzGerald⁴, Robert C. Murphy⁶⁷, John W. Newman⁶⁸, Edward A. Dennis¹⁵, Kim Ekroos⁶⁹, Ginger L. Milne⁷⁰, Miguel A. Gijón⁴¹, Hubert W. Vesper⁷¹, Craig E. Wheelock^{2,72}, Valerie B. O'Donnell⁷³

*Corresponding author. E-mail: nils@schebb-web.de

#Member of the International Lipidomics Society Oxylipin Interest Group.

¹Chair of Food Chemistry, School of Mathematics and Natural Sciences, University of Wuppertal, Germany. ²Unit of Integrative Metabolomics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. ³Applied Analytical Chemistry, University of Duisburg-Essen, Essen, Germany. ⁴Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. ⁵Neonatal Research Group, Health Research Institute La Fe (IIS La Fe), Valencia, Spain. ⁶Department of Chemistry and Biochemistry, Concordia University, Montreal, Canada. ⁷School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand. ⁸Department of Analytical Chemistry, University of Valencia, Burjassot, Spain. ⁹Mass Spectrometry Core Facility, Department of Chemistry, Columbia University, New York, NY, USA. ¹⁰School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA, USA. ¹¹Department of Entomology, University of California, Davis, CA, USA. ¹²Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, University of Greifswald, Germany. ¹³Nutrigenomics Research Group, UCD Conway Institute, School of Public Health, Physiotherapy and Sports Science, University College Dublin, Ireland. ¹⁴Institute for Global Food Security, Queen's University Belfast, Northern-Ireland. ¹⁵Department of Pharmacology and Department of Chemistry and Biochemistry, University of California at San Diego, La Jolla, CA, USA. ¹⁶Division of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, USA. ¹⁷BPG Bio, Framingham, MA, USA. ¹⁸Department of Biochemistry, Institute of Chemistry, University of São Paulo, Brazil. ¹⁹Nestlé Institute of Food Safety and Analytical Sciences, Société des Produits Nestlé, Lausanne, Switzerland. ²⁰Faculty of Medicine, Hebrew University of Jerusalem, Israel. ²¹Department of Chemistry, University of Aveiro, Portugal. ²²Lipidomix GmbH, Berlin, Germany. ²³Shimadzu UK Ltd, Milton Keynes, UK. ²⁴Department Food Science and Technology, University of California, Davis, CA, USA. ²⁵Department of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich Schiller University, Jena, Germany. ²⁶Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Frankfurt am Main, Germany. ²⁷MetaboHUB-MetaToul, I2MC, Université de Toulouse, Inserm, Université Toulouse III – Paul Sabatier (UPS), France. ²⁸Faculty of Medicine, Institute of Clinical Pharmacology, Goethe University Frankfurt, Frankfurt am Main, Germany. ²⁹Fraunhofer Institute for

Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany. ³⁰Fraunhofer Cluster of Excellence of Immune Mediate Diseases CIMD, Frankfurt am Main, Germany. ³¹Signature Research Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore (NUS) Medical School, Singapore. ³²Singapore Lipidomics Incubator, Life Sciences Institute and Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. ³³School of Biosciences & Aston Institute for Membrane Excellence, Aston University, Aston Triangle, Birmingham, UK. ³⁴Aston Medical School, College of Health and Life Sciences, Aston University, Aston Triangle, Birmingham, UK. ³⁵Department of Chemistry and Industrial Chemistry, University of Pisa, Italy. ³⁶Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden. ³⁷Center for Novel Target & Therapeutic Intervention, College of Pharmacy, Chongqing Medical University, Chongqing, P. R. China. ³⁸Center of Membrane Biochemistry and Lipid Research, University Hospital and Faculty of Medicine Carl Gustav Carus of TU Dresden, Dresden, Germany. ³⁹Edward A. Doisy Department of Biochemistry and Molecular Biology, Saint Louis University, St. Louis, MO, USA. ⁴⁰Medical School, Royal Perth Hospital Unit, University of Western Australia, Perth, Australia. ⁴¹Cayman Chemical Company, Ann Arbor, MI, USA. ⁴²Metabolomics and Lipidomics Platform, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland. ⁴³Université Clermont Auvergne, INRAE, UNH, Unité de Nutrition Humaine, CRNH Auvergne, Clermont-Ferrand, France. ⁴⁴College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar⁴⁵Long Loo Lin School of Medicine, National University of Singapore. ⁴⁶Institut des Biomolécules Max Mousseron (IBMM), Pôle Chimie Balard Recherche, CNRS, Université de Montpellier, ENSCN, France. ⁴⁷Department of Kinesiology and Health Sciences, University of Waterloo, Canada. ⁴⁸Centre for Metabolomics and Bioanalysis (CEMBIO), Faculty of Pharmacy, CEU San Pablo University, Madrid, Spain. ⁴⁹Health Sciences Mass Spectrometry Core, University of Pittsburgh, PA, USA. ⁵⁰Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA. ⁵¹Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig Medical Center, Germany. ⁵²Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Département de médecine, Faculté de médecine, Université Laval, Québec City, Canada. ⁵³The Rowett Institute, School of Medicine, Medical Science and Nutrition, University of Aberdeen, UK. ⁵⁴Department of Analytical Chemistry, University of Vienna, Austria. ⁵⁵RIKEN Center for Integrative Medical Sciences (IMS), Yokohama, Kanagawa, Japan. ⁵⁶Indigo BioAutomation, Carmel, IN, USA. ⁵⁷Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology Medicine and Health, University of Manchester, UK. ⁵⁸Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, USA. ⁵⁹Medical Research Council Mitochondrial Biology Unit and Department of Medicine, University of Cambridge, UK. ⁶⁰Institute of Clinical Chemistry and Laboratory Medicine, Institute University Hospital Regensburg, Germany. ⁶¹Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Hale Building for Transformative Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. ⁶²Core Facility Mass Spectrometry, ZMF, Medical University of Graz, Austria. ⁶³Department of Chemistry, University of Washington, Seattle, WA, USA. ⁶⁴Faculty of Chemical Technology, University of Pardubice, Pardubice, Czech Republic. ⁶⁵Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, UK. ⁶⁶Leiden University Medical Center, The Netherlands. ⁶⁷Department of Pharmacology, University of Colorado Denver, Denver, CO, USA. ⁶⁸USDA ARS Western Human Nutrition Research Center and Department of Nutrition, University of California, Davis, CA, USA. ⁶⁹Lipidomics Consulting Ltd., Esbo, Finland. ⁷⁰Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Centre, Nashville, TN, USA. ⁷¹Centers for Disease Control and Prevention, Atlanta, GA, USA. ⁷²Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden. ⁷³School of Medicine, Cardiff University, Heath Park, Cardiff, UK.

Abstract

Several oxylipins are potent lipid mediators that regulate diverse aspects of health and disease and whose quantitative analysis by liquid chromatography–mass spectrometry (LC-MS) presents substantial technical challenges. As members of the lipidomics community, we developed technical recommendations to ensure best practices when quantifying oxylipins by LC-MS.

Lipid signaling mediators are essential factors in health and disease, participating in diverse cellular processes related to inflammation, immunity, development, and homeostasis. A major category of lipid mediators, comprising large families of structurally related fatty acyls, are oxylipins, which include eicosanoids such as prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs) and epoxyeicosatrienoic acids (EETs), all of which are derived from arachidonic acid. Other oxylipins are derived from shorter- or longer-chain polyunsaturated fatty acids (PUFAs), such as octadecanoids or docosanoids, including specialized pro-resolving mediators (SPMs). Whereas most oxylipins are generated by enzymes such as lipoxygenases (LOXs), cyclooxygenases (COXs), and cytochrome P450 monooxygenases (CYPs), they can also be formed nonenzymatically by autoxidation. The relevance of oxylipins to human disease is undisputed. For example, well-known drugs target the prostaglandin pathway to modulate inflammatory diseases, including nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and diclofenac. In addition, aspirin, which blocks thromboxane biosynthesis when used at low doses, is the most widely prescribed drug globally, with a major role in the secondary prevention of cardiovascular diseases and emerging potential in reducing cancer incidence (1).

Eicosanoids derived from arachidonic acid were first discovered in the 1930s by von Euler (2). This was followed by the structural characterization of PGs and TXs in the second half of the 20th century, leading to the awarding of the Nobel Prize to Bergström and Samuelsson in 1982 (3), together with Vane for discovering the mechanism of action of aspirin (4). Since then, additional families were found, and key mechanisms of oxylipin signaling, metabolism, and excretion in urine were revealed in numerous biological and pathophysiological contexts. After their initial discovery, oxylipins were often named based on their cellular source; for example, prostaglandins were first identified in seminal vesicles. Alternatively, they were named based

on a combination of source and chemical structure; for example, with LT being made by white blood cells and carrying a triene motif. Although oxylipins are often described as lipid mediators or autacoids that are secreted by cells to act on receptors locally, the biological functions of many oxylipins are still to be established. Only some, for example, PGs and LTs, have G protein–coupled receptors that are formally validated by the International Union of Pharmacology (IUPHAR). In the LIPID MAPS classification (5), oxylipins are listed under Fatty Acyls, within the main classes, octadecanoids (C₁₈), eicosanoids (C₂₀), and docosanoids (C₂₂).

As more oxylipins continue to be discovered and characterized and interest in their bioactivity and pre-clinical measurement increases, it has become essential for researchers to have access to robust analytical methods that enable their sensitive and selective quantification. It is also important that these methods account for the complexity of oxylipin analysis, while leveraging the high capability of newer-generation liquid chromatography (LC)–tandem mass spectrometry (MS/MS). Over the past 20 years, oxylipin analysis has substantially advanced. Indeed, today’s state-of-the-art, targeted LC-MS/MS assays can routinely quantify more than 100 individual molecular species in small amounts of biofluids or tissue extracts, down to low- or sub-picogram amounts on-column in a single analytical run (see Supplementary Materials). Although this is already transforming research into these lipids, there remains a major need to support researchers new to this field who wish to establish these assays. Oxylipins present unique analytical challenges, including low abundance, rapid metabolism to conjugated or chain-shortened forms, the presence of many closely eluting isomers, and similar fragmentation patterns, especially when generated non-enzymatically. Considering this, quantitative analysis of oxylipin families is technically specialist, requiring both chromatography and MS/MS, as well as the availability of authentic and stable isotope–labelled synthetic analytical standards.

The quantification of oxylipins requires accuracy and precision, as well as correct identification and reporting. Given that some oxylipins are present at extremely low endogenous concentrations, it is important to ensure that their measurement adheres to best practices. More broadly, in the wider field of lipidomics, in response to challenges with data reporting and reproducibility, guidelines have been developed, including a Minimal Reporting Checklist (6, 7). (More information on these specific issues, with references, is provided in the Supplementary Materials). Following from that work, but specifically supporting researchers interested in performing oxylipin analysis, community recommendations have been developed and are presented here. These summarize the key aspects to be considered when establishing and routinely running a targeted LC-MS/MS method for oxylipin quantitation in research settings and describe those parameters that should be reported in publications. Criteria for routine quantitation are proposed, together with parameters to be reported when establishing new methods. Additional methods, such as high-resolution accurate mass analysis, data-dependent and data-independent fragmentation, ion mobility, and MS imaging are not covered, but in general, the same overall criteria for performance described herein should apply. Our recommendations also contain an extended and fully referenced introduction, providing a comprehensive history of the discovery of oxylipins and their MS/MS analysis.

For targeted analysis in a clinical setting, numerous guidelines for bioanalytical methods already exist, for example from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), the Food and Drug Administration (FDA), and the Clinical & Laboratory Standards Institute (CLSI) (8-10). These describe requirements for laboratory methods used in patient care, clinical trials, and diagnostics. However, they do not appropriately address the needs and limitations typically observed in basic research settings aimed at increasing our understanding of the underlying mechanisms of diseases and biological processes. Examples of these limitations include the restricted

availability of standards and reference materials, diversity in sample matrix type and sample origin, as well as the lack of analyte-free matrices. Furthermore, they do not provide specific details related to oxylipins. Addressing this, the new recommendations provide technical advice for oxylipin analysis in laboratories reflecting current state-of-the-art practices in discovery research. Where analysts use oxylipin assays to make measurements for clinical or diagnostic purposes, then the guidelines mentioned earlier also need to be applied.

These community recommendations for laboratory assays for oxylipins were initiated by a working group initially established as an International Lipidomics Society (ILS) Interest Group (https://lipidomicssociety.org/interest_groups/oxylipin-analysis/). After an open advertisement to the biomedical community inviting interested researchers to attend, two webinars were held to discuss basic analytical principles that should be included (87 attendees). After feedback through an online form and by email, a draft was generated and then circulated to the webinar attendees and others for input. After revision, an agreed-upon version was finalized and is presented in the Supplementary Materials. These recommendations are fully aligned with the ILS Minimal Reporting Checklist, which should also be used for data reporting (6).

References and Notes

1. E. Ricciotti, G. A. FitzGerald, Aspirin in the Prevention of Cardiovascular Disease and Cancer. *Annu Rev Med* **72**, 473-495 (2021); published online EpubJan 27 (10.1146/annurev-med-051019-102940).
2. U. S. von Euler, On the specific vasodilating and plain muscle stimulating substances from accessory genital glands in man and certain animals (prostaglandin and vesiglandin). *J. Physiol. (Lond)* **88**, 213 (1936).
3. S. Bergstroem, H. Danielsson, B. Samuelsson, The Enzymatic Formation of Prostaglandin E2 from Arachidonic Acid Prostaglandins and Related Factors 32. *Biochim Biophys Acta* **90**, 207-210 (1964); published online EpubJul 15 (10.1016/0304-4165(64)90145-x).
4. J. R. Vane, Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. *Nat New Biol* **231**, 232-235 (1971); published online EpubJun 23 (10.1038/newbio231232a0).
5. E. Fahy, S. Subramaniam, H. A. Brown, C. K. Glass, A. H. Merrill, Jr., R. C. Murphy, C. R. Raetz, D. W. Russell, Y. Seyama, W. Shaw, T. Shimizu, F. Spener, G. van Meer, M. S. VanNieuwenhze, S. H. White, J. L. Witztum, E. A. Dennis, A comprehensive classification

system for lipids. *J Lipid Res* **46**, 839-861 (2005); published online EpubMay (10.1194/jlr.E400004-JLR200).

6. D. Kopczynski, C. S. Ejsing, J. G. McDonald, T. Bamba, E. S. Baker, J. Bertrand-Michel, B. Brugger, C. Coman, S. R. Ellis, T. J. Garrett, W. J. Griffiths, X. L. Guan, X. Han, M. Horing, M. Holcapek, N. Hoffmann, K. Huynh, R. Lehmann, J. W. Jones, R. Kaddurah-Daouk, H. C. Kofeler, P. J. Meikle, T. O. Metz, V. B. O'Donnell, D. Saigusa, D. Schwudke, A. Shevchenko, F. Torta, J. A. Vizcaino, R. Welte, M. R. Wenk, D. Wolrab, Y. Xia, K. Ekroos, R. Ahrends, G. Liebisch, The Lipidomics Reporting Checklist A framework for transparency of lipidomic experiments and repurposing resource data. *J Lipid Res*, 100621 (2024); published online EpubAug 14 (10.1016/j.jlr.2024.100621).

7. G. Liebisch, K. Ekroos, M. Hermansson, C. S. Ejsing, Reporting of lipidomics data should be standardized. *Biochim Biophys Acta Mol Cell Biol Lipids* **1862**, 747-751 (2017); published online EpubAug (10.1016/j.bbalip.2017.02.013).

8. *International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH): ICH guideline M10 on bioanalytical method validation and study sample analysis* (2022).

9. *Bioanalytical Method Validation Guidance for Industry, FDA/CDER/CVM 2001* (2018).

10. K. L. Lynch, CLSI C62-A: A New Standard for Clinical Mass Spectrometry. *Clin Chem* **62**, 24-29 (2016); published online EpubJan (10.1373/clinchem.2015.238626).

Acknowledgments: The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention/the Agency for Toxic Substances and Disease Registry. Use of trade names is for identification only and does not imply endorsement by the Centers for Disease Control and Prevention, the Public Health Service, and the U.S. Department of Health and Human Services.

Funding: We gratefully acknowledge the following funding sources: LIPID MAPS (MRC MR/Y000064/1 to V.B.O'D.), US National Institutes of Health (R01 GM125944 to F.J.S.; R01 HL132550, P01 HL103455, and R33 HL157069 to B.F.; S10 OD23402 and S10 OD032141 to S.L.G.; U54 NS127758 to B.D.H.; R35 GM139641 to E.A.D.; R21 AG081823 to G.L.M.), US National Institute of Environmental Health Sciences (Z01 ES025034 to D.Z.; R35 ES030443-01 and P42 ES004699 to B.D.H.), US Department of Agriculture (2032-51530-025-00D to J.W.N.), Medical Research Council (MR/Y000064/1 to V.B.O'D.; MC_UU_00028/4 to M.P.M.; BB/W018322/1 to R.D.), European Union (ERC Adv grant No. 101095860 to M.H.; CA19105 to M.F. and R.D.; 847419 to C.S.), Wellcome Trust (220257/Z/20/Z to M.P.M.), German Research Foundation (SCHE 1801 to N.H.S.; FE 1236/5-1 and FE 1236/8-1 to M.F.; SFB 1039/Z01 to R.G. and D.T.), German Federal Ministry of Education and Research (BMBF 031L0315A, DEEP_HCC and 01EJ2205A, and FERROPath to M.F.), São Paulo Research Foundation (FAPESP #2013/07937-8 to S.M.), Carlos III Health Institute (CP21II/00003 to J.K.), MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR (JDC2022-049354-I to A.S.I.), Natural Sciences and Engineering Research Council of Canada (RGPIN-2021-03777 to N.F.), The Portuguese Centre for the Environment and Marine Studies CESAM (UIDB/50017/2020, UIDP/50017/2020, and LA/P/0094/2020 to R.D.), and the Alzheimer's Association (AARGD-22-926459 to I.D.). **Competing interests:** V.B.O'D. is a consultant for Metasight. B.D.H. is a founder of EicOsis Human Health with a potential pharmaceutical in clinical trials whose action depends on altering the profile of inflammatory lipids. K.M. is President and CEO of Cayman Chemical and a supplier of lipid standards. M.G. is a cofounder of the company Enfanos, LLC. B.F. acknowledges a financial interest in Creegh Pharmaceuticals Inc. E.A. Dennis is a cofounder of LipoNexus, Inc. B.A.F. acknowledges an interest in Creegh Pharmaceuticals, Inc.